Epidemiological studies indicate that subjects of the genetically based slow acetylator phenotype may be at higher risk for bladder cancer than fast acetylators, particularly when they are exposed to carcinogenic arylamines: N-acetylation is a detoxification step in the metabolism of some arylamines. We describe two collaborative studies on tobacco smoking, in which markers of internal dose (arylamine-hemoglobin adducts) and markers of genetically based metabolic polymorphism have been coupled. In the first investigation, we found that hemoglobin adducts formed by mononuclear arylamines have high reciprocal correlation coefficients, as do adducts from binuclear arylamines. This tendency of adducts with structurally similar arylamines to correlate reciprocally explains a large proportion ofthe residual variance seen after controlling for smoking habits (number and type of cigarettes). In the second study, the concentration of 4-aminobiphenyl-hemoglobin adducts varied according to three independent determinants: number of cigarettes, type of tobacco (air or flue cured), and acetylator phenotype (slow and fast). The dose-response relationship between the amount of tobacco smoked and level of 4-aminobiphenyl-hemoglobin adducts in the slow acetylators (with an immediate steep increase of the adducts) was different from that in the fast acetylators (with a more regular increase). These findings from "molecular epidemiology" may contribute to an understanding of the role of metabolic polymorphism in human carcinogenesis.
Introduction
Interindividual variability in the metabolism of arylamines has been suggested in several epidemiological investigations to be relevant to human bladder cancer. The purpose of this paper is to review such evidence briefly and to report the relevant findings of two studies on the "molecular epidemiology" of bladder cancer.
Epidemiological Evidence on N-Acetyltransferase Polymorphism and Bladder Cancer Risk N-Acetyltransferase is involved in the detoxication of arylamines, a class of chemicals that includes some wellknown bladder carcinogens. The activity of the enzyme shows genetically based polymorphism in human populations, with a clear-cut distinction between extensive metabolizers, who compose about 30-50% of the population, and poor metabolizers (PM), who represent 50-70% of the general population in western countries. Since some arylamines are potent bladder carcinogens and N-acetylation is involved in their detoxication, one would expect PM to be at higher risk for bladder cancer than extensive metabolizers.
In their seminal report, Cartwright et al.
(1) described a case-control study of 111 bladder cancer cases and 207 controls. The N-acetylation phenotype was assessed by measuring the monoacetyldapsone: dapsone ratio, and 0.3 was used as the cut-off point between the phenotypes. The proportion of PM was 57% among the controls and 67% among the cases; however, this proportion was considerably increased in a group of 23 occupationally exposed cases (with possible exposure to benzidine and 2-naphthylamine). In fact, 22 out of 23 (p = 0.005) were PM; the only fast metabolizer had an adenocarcinoma, i.e., a histologic type different from that of the other 22, which were transitional-cell carcinomas.
The very high proportion of poor acetylators among the occupationally exposed bladder cancer cases described by Cartwright et al. has not been reported by others. A number of case-control studies have shown, however, a slight excess of PM among bladder cancer patients in comparison with controls. Table 1 gives the results of these studies. The numbers are generally small, and the confidence intervals of the odds ratios are large; nevertheless, the qualitative consistency of the findings is intriguing (see also reference 4 for a review In a molecular epidemiology investigation in which we were involved (6), we reported that the quantities of hemoglobin adducts with 3-aminobiphenyl (3-ABP) and 4-ABP were related to the quantity of cigarettes smoked and, in the case of 4-ABP, also to the kind of tobacco smoked (air or flue cured). Air-cured tobacco is known to contain larger amounts of arylamines than flue-cured product and has also been found to be associated with higher risks of bladder cancer in three epidemiological investigations (7) (8) (9) .
In the molecular epidemiology investigation, the quantity and type of tobacco smoked were statistically significantly associated to the quantity of 4-ABP-hemoglobin adducts but could not explain a considerable proportion of the interindividual variation in the amounts of adducts. We reanalyzed the same set of data for smokers in order to ascertain whether the residual, unexplained variation was related to individual differences in susceptibility, possibly due to metabolic characteristics. If individual metabolic differences were responsible for part of the unexplained interindividual variation in the levels of hemoglobin adducts and if chemically similar substances have, at least in part, common metabolic pathways, then the concentrations of adducts with similar amines should be correlated in the same individual, allowing for the amount and type of tobacco smoked. In other words, subjects with high levels of 4-ABP adducts should also have high levels of 3-ABP adducts, allowing for tobacco consumption, and subjects with low levels of 4-ABP should have low levels of 3-ABP.
We considered the data for 25 nonsmokers, 18 smokers of air-cured tobacco, and 40 smokers of flue-cured tobacco, all living in the city of Torino (Thrin). Blood samples were analyzed at the Massachusetts Institute of Technology (Cambridge) for hemoglobin adducts formed with 14 aromatic amines, using gas chromatography-mass spectrometry. The distribution of subjects by number of cigarettes smoked the day before collection is shown in Table 2 .
For all quantities, except for 3, 8, 12, 14, 16, 17, and 18 cigarettes, at least two subjects reported exactly the same amount smoked. Only these 54 subjects were included in the statistical analyses as at least two smokers ofthe same amount were necessary to study interindividual variability not explained by the amount smoked. A model was fitted by the least-squares method for each aromatic amine, including the kind and amount of tobacco smoked; statistical residuals from this model were computed. Residuals are the differences between the observed levels of adducts and those expected on the basis of the model. This procedure is equivalent to computing the difference between the amount of adducts in each subject and the mean for all subjects who smoked exactly the same number of cigarettes, after adjusting for kind oftobacco. Since, for all amines, the residuals showed a log-normal distribution, the logarithm of adduct concentration was also used. A correlation matrix of the residuals for the 14 aromatic amines was computed, and a principal component analysis was performed. The purpose of principal component analysis is to determine factors (i.e., principal components) in such a way as to explain as much of the total variation in the data as possible. The results of this analysis are reported in Table 3 . Within each principal component ("factor"), the correlation coefficient of each arylamine with the factor is reported. The first principal component explains 49% of total variance and is related to all substances except 3-ABP, 4-ABP, and 2-naphthylamine; the second principal component explains a further 16% of the total variance and includes 3-ABP, 4-ABP, and 2-naphthylamine, whereas the coefficients for all other amines (except p-toluidine) are This finding seems to suggest that two different metabolic pathways are involved -one for mononuclear and the other for binuclear aromatic amines-and that interindividual variability exists for these pathways. Such variability would explain a considerable proportion of the differences in levels of hemoglobin adducts that are not explained by smoking habits.
N-Acetyltransferase Polymorphism and 4-ABP-Hemoglobin Adducts
Several sources of information indicate that 4-ABP is related to bladder carcinogenesis in smokers: two studies on hemoglobin adducts, including that already mentioned (6,11); one study on DNA adducts in exfoliated bladder cells (12) ; one study of bladder biopsy samples from humans (13) ; and studies on bladder biopsy samples from dogs. Thlaska et al. (14) showed that administration of 4-ABP to dogs resulted in formation of a main DNA adduct in bladder cells, N-(deoxyguanosin-8-yl)-4-ABP. Subsequently, they studied DNA adducts in biopsy samples from 42 subjects with bladder cancer and again found that N-(deoxyguanosin-8-yl)-4-ABP was one of the main adducts in smokers (13) . Finally, a comprehensive collaborative investigation has been conducted among 97 volunteers in Torino to measure the levels of 4-ABP adducts with hemoglobin (11) and with DNA in exfoliated bladder cells (12) . The levels of hemoglobin adducts clearly correlate with the number of cigarettes smoked, with urinary cotinine and nicotine, and with the type of tobacco used (air or flue cured). In addition, the levels of 2 out of 12 DNA adducts found among smokers were clearly correlated with both the number of cigarettes smoked and the concentration of 4-ABP-hemoglobin adducts; one of the two DNA adducts was quite similar to N-(deoxyguanosin-8-yl)-4-aminobiphenyl (12) . There are good reasons to believe, therefore, that 4-ABP, and perhaps other arylamines, play an important role in smoking-induced bladder carcinogenesis.
In the study mentioned above on 97 volunteers, the concentration of 4-ABP-hemoglobin adducts was also measured according to N-acetylation phenotype (defined on the basis of the ratio of two metabolites of caffeine, 5-acetylamino-6-formylamino-3-methyluracil, and 17-methylxanthine; measurements made at the National Cen- ter for Toxicological Research, Jefferson, AR). The concentration of adducts is clearly higher in slow acetylators (Table 4) . When smoking habits (dose, type oftobacco) and metabolic phenotype were included in a multivariate model, an independent, statistically significant contribution of the latter was found. This finding agrees with a priori expectations, since N-acetylation is expected to deactivate 4-ABP, thus preventing covalent binding to macromolecules.
DoseResponse Relationships
The shape of dose-response curves in cancer epidemiology has usually been interpreted to infer the number of stages in the carcinogenic process, within the frame of multistage carcinogenesis. An example is the quadratic dose-response relationship seen between the number of cigarettes smoked and the risk for lung cancer; the inference is that tobacco smoke acts at two stages of the carcinogenic process in the lung (15) . The dose-response relationship can also be an expression of other phenomena; one of these is metabolic polymorphism within the study population, i.e., the presence of subgroups with different susceptibilities to the action of carcinogens.
In epidemiological studies of bladder cancer, a convex dose-response relationship has been observed repeatedly between the number of cigarettes smoked and the relative risk, rather than the linear or exponential curve seen in lung cancer (16) . In other words, the relative risk increases quickly, then seems to reach a plateau. For example, in the largest case-control study reported, the relative risks by number of cigarettes smoked (with nonsmokers as the reference category) were: < 20, 1.8 (18) . In other investigations, however, the plateau was less clear (16) .
A convex dose-response curve was also observed for the correlation of the concentration of 4-ABP-hemoglobin adducts with markers of recent smoking (number of cigarettes, urinary cotinine and nicotine) (6, 11) . Such a relationship would be expected a priori if the population included two subgroups -one that metabolizes the relevant chemical rapidly and the other, slowly. In fact, when the data on hemoglobin adducts were subdivided according to metabolic phenotype (slow or fast acetylator), the picture shown in Table 5 emerged. Slow acetylators clearly have a high level of adducts at low levels of smoking, whereas the curve for fast acetylators increases more regularly. The association of the two curves leads to a less than linear relationship. The intercept ofthe curve for slow acetylators is 72 pg/g hemoglobin, which is significantly different from the intercept for fast acetylators (p = 0.01). Unfortunately, these observations are still based on small numbers, as expressed by the large standard errors in Table 5 , and warrant further investigation.
It would be an oversimplification to conclude that the convex dose-response curve observed between the number of cigarettes smoked and the relative risk for bladder cancer indicates the same phenomenon as hypothesized for hemoglobin adducts. In fact, carcinogenesis is more complex than the simple binding of arylamines to macromolecules. Nevertheless, the similarity of the doseresponse curves is suggestive.
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